| HOUSE OF LORDS | SESSION 2003–04 [2004] UKHL 46 |
on appeal from: [2002] EWCA Civ 1096
OPINIONS
OF THE LORDS OF APPEAL
FOR JUDGMENT IN THE CAUSE
Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion Roussel Limited and others (Respondents) Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion Roussel Limited and others (Appellants) (Conjoined Appeals) ON THURSDAY 21 OCTOBER 2004 The Appellate Committee comprised: Lord Hoffmann Lord Hope of Craighead Lord Rodger of Earlsferry Lord Walker of Gestingthorpe Lord Brown of Eaton-under-Heywood HOUSE OF LORDS OPINIONS OF THE LORDS OF APPEAL FOR JUDGMENT IN THE CAUSE Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion
Roussel Limited and others (Respondents)
Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion
Roussel Limited and others (Appellants)
(Conjoined Appeals)
[2004] UKHL 46
LORD HOFFMANN
My Lords,
The proceedings
1. Kirin-Amgen Inc (“Amgen”), a Californian pharmaceutical company, is the proprietor of a European patent (EP 0148605B2) relating to the production of erythropoietin (“EPO”) by recombinant DNA technology. EPO is a hormone made in the kidney which stimulates the production of red blood cells by the bone marrow. The discovery by Amgen of a method of making EPO artificially for use as a drug was a significant advance in the treatment of anaemia, particularly when associated with kidney failure. Amgen market it under the name Epogen and the patent (which will expire on 11 December 2004) has been very profitable.
2. These appeals arise out of a dispute concerning both the validity and infringement of the patent between Amgen and two other pharmaceutical companies. Transkaryotic Therapies Inc (“TKT”) is a Massachusetts corporation. It has also developed a method of making EPO, which it markets under the name Dynepo. It uses a process which it calls “gene activation” and the product been referred to in this appeal as “GA-EPO”. Hoechst Marion Roussel Ltd (“Hoechst”) is the English subsidiary of a well-known multinational pharmaceutical company which has been proposing to import GA-EPO into the United Kingdom. In three consolidated actions, Amgen claims that GA-EPO infringes the claims of the patent in suit and TKT and Hoechst claim a declaration of non-infringement and revocation of the patent. I shall for convenience refer to both Hoechst and TKT as “TKT” but it should be borne in mind that the only allegations of infringement in the United Kingdom arise out of the importation of the drug by Hoechst.
3. The science upon which recombinant DNA technology is based has been described in a number of judgments, not least in the admirable account given by Neuberger J in this case, much of which was reproduced verbatim by the Court of Appeal. I do not propose to repeat these passages but gratefully adopt them and will largely take them as read.
The race for EPO
4. The technology for manufacturing proteins (“polypeptides”) by the expression of recombinant DNA developed rapidly after the mid- 1970s. The speed of development is illustrated by the decision of your Lordships’ House in Biogen Inc v Medeva plc [1997] RPC…
Keep reading for free
Create a free CaseChat account to read Kirin-Amgen Inc v Hoechst Marion Roussel Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] UKHL 46
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.